IDEXX Laboratories, Inc. (IDXX) Position Lifted by Gotham Asset Management LLC

Gotham Asset Management LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 109.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,620 shares of the company’s stock after acquiring an additional 2,411 shares during the quarter. Gotham Asset Management LLC’s holdings in IDEXX Laboratories were worth $722,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. New York State Common Retirement Fund raised its stake in shares of IDEXX Laboratories by 5.9% during the 3rd quarter. New York State Common Retirement Fund now owns 252,700 shares of the company’s stock worth $39,292,000 after acquiring an additional 14,000 shares in the last quarter. Legal & General Group Plc increased its stake in IDEXX Laboratories by 1.1% during the 3rd quarter. Legal & General Group Plc now owns 434,703 shares of the company’s stock valued at $67,592,000 after purchasing an additional 4,888 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in IDEXX Laboratories by 8.4% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,098 shares of the company’s stock valued at $1,104,000 after purchasing an additional 551 shares in the last quarter. Schroder Investment Management Group increased its stake in IDEXX Laboratories by 29.3% during the 3rd quarter. Schroder Investment Management Group now owns 86,418 shares of the company’s stock valued at $13,341,000 after purchasing an additional 19,562 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in IDEXX Laboratories by 7.8% during the 3rd quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock valued at $52,706,000 after purchasing an additional 24,510 shares in the last quarter. Hedge funds and other institutional investors own 87.37% of the company’s stock.

How to Become a New Pot Stock Millionaire

IDXX has been the topic of a number of recent analyst reports. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Piper Jaffray initiated coverage on shares of IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target on the stock. Bank of America upped their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and an average target price of $194.00.

Shares of IDEXX Laboratories stock opened at $191.39 on Monday. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a 12-month low of $146.09 and a 12-month high of $207.14. The company has a market cap of $16,674.47, a price-to-earnings ratio of 58.35, a P/E/G ratio of 2.35 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.58 EPS. research analysts forecast that IDEXX Laboratories, Inc. will post 4.11 EPS for the current year.

In other news, Chairman Jonathan W. Ayers sold 36,000 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $179.28, for a total value of $6,454,080.00. Following the sale, the chairman now directly owns 1,077,112 shares of the company’s stock, valued at approximately $193,104,639.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at $179,910,017.36. The disclosure for this sale can be found here. Insiders sold a total of 91,736 shares of company stock worth $16,193,502 over the last ninety days. Insiders own 2.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.wkrb13.com/2018/04/02/idexx-laboratories-inc-idxx-position-lifted-by-gotham-asset-management-llc.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply